POLB and neoplasm: The results of CCK-8, flow cytometry and in vivo tumor growth assays indicated that polβ−/− group cells are more sensitive than wild-type to 5-FU and cisplatin, and A613T, G462T mutation weaken the sensitivity of cells to 5-FU and cisplatin.